Ann: Investor Update, page-74

spot on, companies like this not just OSL really need to watch this as their materials are publicly accessible, no question that a pancreatic cancer patient could look at the chart and conclude, wrongly, they'd double survival or get 8 extra months life if they receive osl device.
did you notice company seems to have quietly dropped its surgical resection slide that talked about oncosil giving 3 times resection rate
It was in the capital raise presentation from May but is absent from most recent presentation. As it's a massive sales message for company, you surely don't drop something like that without good reason.